Skip to main content
SpringerLink
Log in

RG7314

Encyclopedia of Autism Spectrum Disorders

  • 283 Accesses

Synonyms

RO 5028442; RO-5285119

Definition

RG7314 is an investigational drug candidate developed by Hoffman-La Roche for the potential treatment of autism spectrum disorder (ASD). It is a nonpeptide vasopressin receptor antagonist (vaptan) with reported selectivity for the vasopressin V1a receptor. RG7314 is the first vaptan drug to be tested in psychiatry, and its therapeutic potential is yet unknown. The drug is currently undergoing a phase II clinical trial in adult males with ASD for the alleviation of core ASD symptoms. To date, data on the safety or efficacy of RG7314 have not been published.

Vasopressin, also known as antidiuretic hormone, is a small peptide produced in the hypothalamus. It is a major physiological regulator of water homeostasis, affecting urine concentration and blood volume. Vasopressin binds to three different receptors, V1a, V1b (also called V3), and V2. Activation of V1a receptors on vascular smooth muscle causes vasoconstriction, and activation of V2...

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References and Readings

  • A Phase 1, Randomized, Double-blind, Placebo-controlled Crossover Study of RG7314 on the Potential Regulation of Higher Brain Functions in Healthy Male Participants: Proof of Mechanism. (2014). Retrieved from https://clinicaltrials.gov/show/NCT02205073 (Identification no. NCT02205073).

  • Ali, F., Guglin, M., Vaitkevicius, P., & Ghali, J. K. (2007). Therapeutic potential of vasopressin receptor antagonists. Drugs, 67(6), 847–858.

    Article  PubMed  Google Scholar 

  • Baribeau, D. A., & Anagnostou, E. (2015). Oxytocin and vasopressin: Linking pituitary neuropeptides and their receptors to social neurocircuits. Frontiers in Neuroscience, 9, 335.

    Article  PubMed  PubMed Central  Google Scholar 

  • Bolognani, F., del Valle Rubido, M., Squassante, L., Wandel, C., Liogier D’ardhuy, X., Boak, L., … Umbricht, D. (2017, May). Results of a phase 2 randomized double-blind Placebo controlled study (VANILLA) investigating the efficacy and safety of a V1a antagonist (RG7314) in adult men with ASD. Paper presented at the international meeting for autism research, San Francisco.

    Google Scholar 

  • Meyer-Lindenberg, A., Domes, G., Kirsch, P., & Heinrichs, M. (2011). Oxytocin and vasopressin in the human brain: Social neuropeptides for translational medicine. Nature Reviews Neuroscience, 12(9), 524–538.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Yale Child Study Center, 230 South Frontage Road, New Haven, CT, 06520, USA

    Zachary Williams & James C McPartland

Authors
  1. Zachary Williams
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. James C McPartland
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zachary Williams .

Editor information

Editors and Affiliations

  1. Yale Child Study Center, New Haven, Connecticut, USA

    Fred R. Volkmar

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer Science+Business Media LLC

About this entry

Cite this entry

Williams, Z., McPartland, J.C. (2017). RG7314. In: Volkmar, F. (eds) Encyclopedia of Autism Spectrum Disorders. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-6435-8_102135-1

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-6435-8_102135-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-6435-8

  • Online ISBN: 978-1-4614-6435-8

  • eBook Packages: Springer Reference Behavioral Science and PsychologyReference Module Humanities and Social SciencesReference Module Business, Economics and Social Sciences

Publish with us

Policies and ethics

Chapter history

  1. Latest

    Balovaptan
    Published:
    21 March 2018

    DOI: https://doi.org/10.1007/978-1-4614-6435-8_102135-2

  2. Original

    RG7314
    Published:
    29 July 2017

    DOI: https://doi.org/10.1007/978-1-4614-6435-8_102135-1

Search

Navigation